Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors

Core Insights - Novo Nordisk's stock closed at $53.38, down 2.56% from the previous day, underperforming the S&P 500, which lost 0.53% [1] - The stock has decreased by 7.99% over the past month, contrasting with the Medical sector's gain of 3.64% and the S&P 500's gain of 1.13% [1] Earnings Expectations - The upcoming earnings report on November 5, 2025, is anticipated to show an EPS of $0.75, a decline of 16.67% year-over-year [2] - Revenue is projected at $11.88 billion, reflecting a 13.12% increase compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are estimated at $3.66 per share, representing an 11.59% increase from the previous year, with revenue expected to reach $48.96 billion, a 16.29% increase [3] Analyst Estimates and Market Sentiment - Recent changes in analyst estimates for Novo Nordisk are crucial as they indicate short-term business trends, with positive revisions suggesting optimism [3] - The Zacks Consensus EPS estimate has decreased by 5.17% in the past month, and Novo Nordisk currently holds a Zacks Rank of 4 (Sell) [5] Valuation Metrics - Novo Nordisk has a Forward P/E ratio of 14.96, which is higher than the industry average of 14.66 [6] - The company has a PEG ratio of 2.49, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.62 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]